ML336

ML336 is quinazolinone-based inhibitor against venezuelan equine encephalitis virus (VEEV), with IC50s of 32, 20, and 42 nM for VEEV TC-83 CPE , VEEV V3526 CPE, VEEV Wild Type CPE, respectively. ML336 potently inhibits a VEEV-induced cytopathic effect in three strains of the virus (TC-83, V3526, and wild type Trinidad donkey) in the low nanomolar range[1].

Product Specifications

CAS Number

[1613465-33-0]

UNSPSC

12352005

Target

Virus Protease

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/ml336.html

Purity

99.65

Solubility

DMSO : 20 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=CC=C1)C2=CC([N+]([O-])=O)=CC=C2/N=C3N(C)CCN(C)C/3

Molecular Formula

C19H21N5O3

Molecular Weight

367.40

References & Citations

[1]Chung D, et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV) . 2012 Dec 17 [updated 2013 Nov 7]. In: Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD) : National Center for Biotechnology Information (US) ; 2010–.|[2]Donghoon Chung 1, et al. ML336: Development of Quinazolinone-Based Inhibitors Against Venezuelan Equine Encephalitis Virus (VEEV) .